Next Article in Journal
Evidence for Transient Receptor Potential (TRP) Channel Contribution to Arthritis Pain and Pathogenesis
Next Article in Special Issue
Antidiabetic Drugs in NAFLD: The Accomplishment of Two Goals at Once?
Previous Article in Journal
Oxidative Stress and Cardiovascular Complications in Chronic Kidney Disease, the Impact of Anaemia
Article Menu
Issue 4 (December) cover image

Export Article

Open AccessReview
Pharmaceuticals 2018, 11(4), 104; https://doi.org/10.3390/ph11040104

Obeticholic Acid: A New Era in the Treatment of Nonalcoholic Fatty Liver Disease

1
Department of Health Sciences, University “Magna Graecia”, Viale Europa-Germaneto, 8810 Catanzaro, Italy
2
School of Medicine, Taras Shevchenko National University of Kyiv, Volodymyrska Street 64/13, 01601 Kiev, Ukraine
3
Greenwood Genetic Center, Greenwood, SC 29646, USA
4
School of Health Research, Clemson University, Clemson, SC 29646, USA
5
Department of Endocrinology, Bogomolets National Medical University, Pushkinska 22a, 01610 Kiev, Ukraine
*
Author to whom correspondence should be addressed.
Received: 11 September 2018 / Revised: 1 October 2018 / Accepted: 3 October 2018 / Published: 11 October 2018
(This article belongs to the Special Issue New Advances in the Treatment of Nonalcoholic Fatty Liver Disease)
Full-Text   |   PDF [232 KB, uploaded 11 October 2018]   |  

Abstract

The main treatments for patients with nonalcoholic fatty liver disease (NAFLD) are currently based on lifestyle changes, including ponderal decrease and dietary management. However, a subgroup of patients with nonalcoholic steatohepatitis (NASH), who are unable to modify their lifestyle successfully, may benefit from pharmaceutical support. Several drugs targeting pathogenic mechanisms of NAFLD have been evaluated in clinical trials for the treatment of NASH. Farnesoid X receptor (FXR) is a nuclear key regulator controlling several processes of the hepatic metabolism. NAFLD has been proven to be associated with abnormal FXR activity. Obeticholic acid (OCA) is a first-in-class selective FXR agonist with anticholestatic and hepato-protective properties. Currently, OCA is registered for the treatment of primary biliary cholangitis. However, promising effects of OCA on NASH and its metabolic features have been reported in several studies. View Full-Text
Keywords: nonalcoholic fatty liver disease; nonalcoholic steatohepatitis; fibrosis; obeticholic acid; farnesoid X receptor; metabolism nonalcoholic fatty liver disease; nonalcoholic steatohepatitis; fibrosis; obeticholic acid; farnesoid X receptor; metabolism
Figures

Graphical abstract

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).
SciFeed

Share & Cite This Article

MDPI and ACS Style

Abenavoli, L.; Falalyeyeva, T.; Boccuto, L.; Tsyryuk, O.; Kobyliak, N. Obeticholic Acid: A New Era in the Treatment of Nonalcoholic Fatty Liver Disease. Pharmaceuticals 2018, 11, 104.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Pharmaceuticals EISSN 1424-8247 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top